Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study

Inflammatory Bowel Diseases

Volumn 22, Issue 7, 2016, Pages 1639-1646

  Pavlidis, Polychronis ^a,b   Stamoulos, Panagiotis ^a   Abdulrehman, Answar ^a   Kerr, Patrick ^c   Bull, Claire ^a   Duley, John ^d   Ansari, Azhar ^a  

^a EAST SURREY HOSPITAL   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c East Surrey Clinical Commissioning Group   (United Kingdom)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

allopurinol; azathioprine; inflammatory bowel disease

Indexed keywords

ALLOPURINOL; AMINOTRANSFERASE; AZATHIOPRINE; C REACTIVE PROTEIN; ANTIMETABOLITE; IMMUNOSUPPRESSIVE AGENT; METHYLTRANSFERASE; THIOPURINE METHYLTRANSFERASE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE MARROW TOXICITY; COMBINATION DRUG THERAPY; CROHN DISEASE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HAIR LOSS; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PANCREATITIS; PRIORITY JOURNAL; RASH; REMISSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ULCERATIVE COLITIS; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; HEMATOLOGIC DISEASE; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; TOXIC HEPATITIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; ANTIMETABOLITES; AZATHIOPRINE; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHEMICAL AND DRUG INDUCED LIVER INJURY; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEMATOLOGIC DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; MALE; METHYLTRANSFERASES; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84976324424     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000827     Document Type: Article

References (49)

1. Ansari A, Elliott T, Baburajan B, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:734-741
2. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:640-647
3. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007;5: 209-214
4. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005;22:441-446
5. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996;39: 401-406
6. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001-2008
7. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713
8. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002; 122:904-915
9. Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363-369
10. Smith MA, Blaker P, Marinaki AM, et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis. 2012;6:905-912
11. Gonzalez-Lama Y, Bermejo F, Lopez-Sanroman A, et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther. 2011;34:544-554
12. van Egmond R, Chin P, Zhang M, et al. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther. 2012;35:1181-1189
13. Dassopoulos T, Dubinsky MC, Bentsen JL, et al. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther. 2014;39:163-175
14. Reinshagen M, Schutz E, Armstrong VW, et al. 6-thioguanine nucleotideadapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem. 2007;53:1306-1314
15. Coenen MJ, de Jong DJ, van Marrewijk CJ, et al. Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015;149:907-917. e907
16. Duley JA, Chocair PR, Florin TH. Observations on the use of allopurinol in combination with azathioprine or mercaptopurine. Aliment Pharmacol Ther. 2005;22:1161-1162
17. Duley JA, Florin TH. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther Drug Monit. 2005;27:647-654
18. van Asseldonk DP, Sanderson J, Boer NK, et al. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease-proceedings of the first Thiopurine Task Force Meeting. Dig Liver Dis. 2011;43:270-276
19. Friedman AB, Sparrow MP, Gibson PR. The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders. Int J Rheumatic Dis. 2014;17:132-141
20. Lancaster DL, Patel N, Lennard L, et al. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 2002;50: 33-36
21. Cao ZH, Wei ZY, Zhu QY, et al. HLA-B 58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics. 2012;13: 1193-1201
22. Ansari AR, Duley JA. Azathioprine co-therapy with allopurinol for inflammatory bowel disease: trials and tribulations. Rev Assoc Med Bras. 2012;58(suppl 1):28-33
23. Higgins PD, Schwartz M, Mapili J, et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005;54:782-788
24. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32
25. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010;8:357-363
26. Leiper K, Woolner J, Mullan MM, et al. A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease. Gut. 2001;49:790-794
27. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr. 1992;583:83-90
28. Ford LT, Berg JD. Determination of thiopurine S-methyltransferase activity in erythrocytes using 6-thioguanine as substrate and a non-extraction liquid chromatographic technique. J Chromatogr B Anal Technol Biomed Life Sci. 2003;798:111-115
29. Williams CD, McGill MR, Lebofsky M, et al. Protection against acetaminophen-induced liver injury by allopurinol is dependent on aldehyde oxidase-mediated liver preconditioning. Toxicol Appl Pharmacol. 2014;274:417-424
30. Govani SM, Higgins PD. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis. 2010;4: 444-449
31. Elion EB, Callahan SW, Hitchings GH, et al. Experimental, clinical, and metabolic studies of thiopurines. Cancer Chemother Rep. 1962;16: 197-202
32. Walker RI, Horvath WL, Rule WS, et al. The failure of allopurinol to enhance 6-mercaptopurine toxicity in rabbits. Cancer Res. 1973;33: 755-758
33. Elion GB. The purine path to chemotherapy. Science. 1989;244:41-47
34. Pericleous M, Abdulrehman A, Bull C, et al. Outcomes of increased dose of allopurinol in Ibd patients who developed hepatotoxicity on low azathioprine and allopurinol co-therapy treatment. Gut. 2014;63: A84-A85
35. Tapner MJ, Jones BE, Wu WM, et al. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J Hepatol. 2004;40:454-463
36. Ohta Y, Matsura T, Kitagawa A, et al. Xanthine oxidase-derived reactive oxygen species contribute to the development of D-galactosamineinduced liver injury in rats. Free Radic Res. 2007;41:135-144
37. Chiu ML, Hu M, Ng MH, et al. Association between HLA-B 58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol. 2012;167:44-49
38. Chande N, Patton PH, Tsoulis DJ, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2015;10:CD000067
39. Newman WG, Payne K, Tricker K, et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics. 2011;12: 815-826
40. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New Engl J Med. 2010;362: 1383-1395
41. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:973-983
42. Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:331-342
43. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2013;4:CD000545
44. Ansari A, Sanderson JD. TPMT Testing: Is it Essential? Clinical Dilemmas in Inflammatory Bowel Disease. Blackwell Publishing Ltd; 2007: 40-44
45. Ansari A, Escudier M, Shobowala-Barkre E, et al. Responses to low dose azathioprine in patients with heterozygous thiopurine methyl transferase deficiency. Gastroenterology. 2001;3175:A639
46. Ansari A, EscudierM, Marinaki A, et al. Treatment of zero and intermediate TPMT patients with a tailored dose of azathioprine. Gut. 2003;52:A64
47. Pavlidis P, Ansari A, Duley J, et al. Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study. Inflamm Bowel Dis. 2014;20:2239-2246
48. Ansari A, Elliott T, Fong F, et al. Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm Bowel Dis. 2008; 14:1399-1405
49. Oancea I, Png CW, Das I, et al. A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity. Gut. 2013;62:594-605